BioAgilytix, a leading bioanalytical testing laboratory specializing in immunoassays and cell-based assays, has validated Meso Scale Discovery’s V-PLEX™ Human Cytokine 30-plex assay, making it the first CRO able to offer the validation to clients. The 30-plex assay consists of three optimized panels with proven specificity for high performance and efficient multiplexing. The panels, ProInflammatory Panel I (human), Cytokine Panel I (human), and Chemokine Panel I (human), are for use with cell culture supernatants, serum, plasma, and urine; and they include lot-to-lot reproducibility with inter-lot bridging to support long term studies.
Dr. Afshin Safavi, BioAgilytix Founder and Chief Scientific Officer, notes that “Our close partnership with Meso Scale Discovery gives BioAgilytix early access to their new and most innovative assays. The 30-plex assay offers the high sensitivity and wide dynamic range we have come to expect on the MSD® platform, in a highly efficient multiplexed format. The flexibility and attractive pricing of the panels make this assay very attractive to our clients.”
“This partnership fits perfectly into Meso Scale Discovery’s mission of developing novel biomarkers tests for use in research and diagnostics,” said Jacob Wohlstadter, President and CEO of Meso Scale Discovery. “BioAgilytix is a leading bioanalytical lab that pairs well with our experience in developing high-quality assays.”
About Meso Scale Discovery www.mesoscale.com®
Meso Scale Discovery (MSD), a division of Meso Scale Diagnostics, LLC develops and markets solutions for multiplex biological assays, including assays for biomarkers, cytokines and phosphoproteins. MSD’s platform is based on MULTI-ARRAY® technology, a proprietary combination of patterned arrays and electrochemiluminescence detection, enabling large numbers of measurements with exceptional sensitivity, wide dynamic range and convenience.
About BioAgilytix www.bioagilytix.com
BioAgilytix is a leading bioanalytical testing laboratory specializing in large-molecule bioanalysis. Located in North Carolina’s Research Triangle, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assays services supporting the development and release testing of biologics and small molecule therapeutics. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP.
Our team of highly experienced scientific and QA professionals ensures high quality science, sample and data integrity, and regulatory compliance through all phases of clinical development enabling BioAgilytix to become a trusted partner to 6 out of the top 10 global pharmaceutical and biotech companies.